{"product_id":"recombinant-human-vegfr2-flk-1-kdr-protein-fc-tag-active","title":"Recombinant Human VEGFR2\/Flk-1\/KDR Protein (Fc Tag)(Active)","description":"\u003ch2\u003eRecombinant Human VEGFR2\/Flk-1\/KDR Protein (Fc Tag)(Active)\u003c\/h2\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ctable style=\"height: 29.5938px;\" width=\"503\" data-mce-style=\"height: 29.5938px;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"height: 10px;\" data-mce-style=\"height: 10px;\"\u003e\n\u003ctd style=\"width: 164.547px; height: 10px;\" width=\"137\" data-mce-style=\"width: 164.547px; height: 10px;\"\u003eSKU #\u003c\/td\u003e\n\u003ctd height=\"38\" class=\"xl65\" width=\"106\" style=\"height: 10px; width: 367.453px;\"\u003ePKSH031931\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 19.5938px;\" data-mce-style=\"height: 19.5938px;\"\u003e\n\u003ctd style=\"width: 164.547px; height: 19.5938px;\" data-mce-style=\"width: 164.547px; height: 19.5938px;\"\u003eExpression Host\u003c\/td\u003e\n\u003ctd style=\"width: 367.453px; height: 19.5938px;\"\u003eHEK293 Cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"font-size: 0.875rem;\" data-mce-style=\"font-size: 0.875rem;\"\u003eDescription\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"dt01\" id=\"dt_tab3\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"dt01\"\u003e\n\u003cdiv id=\"dt_tab1\" class=\"dt01\"\u003e\n\u003ctable class=\"pro-table\" style=\"width: 104.745%; height: 270.312px;\" data-mce-style=\"width: 104.745%; height: 270.312px;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"height: 117.562px;\" data-mce-style=\"height: 117.562px;\"\u003e\n\u003ctd style=\"width: 30.6338%; height: 54.547px;\" width=\"170\"\u003eSynonyms\u003c\/td\u003e\n\u003ctd style=\"width: 69.0141%; height: 54.547px;\"\u003eCD309, FLK-1, FLK1, Fetal liver kinase 1, Flk-1, KDR, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, VEGFR, VEGFR-2, VEGFR2, Vascular endothelial growth factor receptor 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 15.5938px;\" data-mce-style=\"height: 15.5938px;\"\u003e\n\u003ctd style=\"width: 30.6338%; height: 19.5938px;\"\u003eSpecies\u003c\/td\u003e\n\u003ctd style=\"width: 69.0141%; height: 19.5938px;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 19.5938px;\" data-mce-style=\"height: 19.5938px;\"\u003e\n\u003ctd style=\"width: 30.6338%; height: 19.5938px;\" width=\"170\"\u003eExpression Host\u003c\/td\u003e\n\u003ctd style=\"width: 69.0141%; height: 19.5938px;\"\u003eHEK293 Cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 19.5938px;\" data-mce-style=\"height: 19.5938px;\"\u003e\n\u003ctd style=\"width: 30.6338%; height: 19.5938px;\"\u003eSequence\u003c\/td\u003e\n\u003ctd style=\"width: 69.0141%; height: 19.5938px;\"\u003eMet 1-Glu 764\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 19.5938px;\" data-mce-style=\"height: 19.5938px;\"\u003e\n\u003ctd style=\"width: 30.6338%; height: 19.5938px;\"\u003eAccession\u003c\/td\u003e\n\u003ctd style=\"width: 69.0141%; height: 19.5938px;\"\u003eNP_002244.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 19.5938px;\" data-mce-style=\"height: 19.5938px;\"\u003e\n\u003ctd style=\"width: 30.6338%; height: 39.1875px;\"\u003eCalculated Molecular Weight\u003c\/td\u003e\n\u003ctd style=\"width: 69.0141%; height: 39.1875px;\"\u003e109 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 19.5938px;\" data-mce-style=\"height: 19.5938px;\"\u003e\n\u003ctd style=\"width: 30.6338%; height: 39.1875px;\"\u003eObserved Molecular Weight\u003c\/td\u003e\n\u003ctd style=\"width: 69.0141%; height: 39.1875px;\"\u003e150-160 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 19.5938px;\" data-mce-style=\"height: 19.5938px;\"\u003e\n\u003ctd style=\"width: 30.6338%; height: 19.5938px;\"\u003eTag\u003c\/td\u003e\n\u003ctd style=\"width: 69.0141%; height: 19.5938px;\"\u003eC-hFc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 137.156px;\"\u003e\n\u003ctd style=\"width: 30.6338%; height: 137.156px;\"\u003eBio-activity\u003c\/td\u003e\n\u003ctd style=\"width: 69.0141%; height: 137.156px;\"\u003e1. Immobilized recombinant human VEGFA at 1. 25 μg\/ml (100 μl\/well) can bind VEGFR2 with a linear range of 1.25-40.0 ng\/ml. 2. Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 20-120 ng\/mL in the presence of 10 ng\/mL recombinant human VEGF165.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n  \u003c\/div\u003e\n\u003cdiv id=\"dt_tab1\" class=\"dt01\"\u003e\u003c\/div\u003e\n\u003cdiv id=\"dt_tab1\" class=\"dt01\"\u003e\u003c\/div\u003e\n\u003cdiv id=\"dt_tab2\" class=\"dt01 detail_section\"\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan class=\"title\"\u003eProperties\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable style=\"width: 100%; height: 305.5px;\" class=\"dtl_table\" data-mce-style=\"width: 100%; height: 305.5px;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"height: 19.5938px;\" data-mce-style=\"height: 19.5938px;\"\u003e\n\u003ctd style=\"width: 17.1587%;\"\u003ePurity\u003c\/td\u003e\n\u003ctd style=\"width: 82.4723%;\"\u003e\u0026gt; 90 % as determined by reducing SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 19.5938px;\" data-mce-style=\"height: 19.5938px;\"\u003e\n\u003ctd style=\"width: 17.1587%;\"\u003eEndotoxin\u003c\/td\u003e\n\u003ctd style=\"width: 82.4723%;\"\u003e\u0026lt; 1.0 EU per μg of the protein as determined by the LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 78.375px;\" data-mce-style=\"height: 78.375px;\"\u003e\n\u003ctd style=\"width: 17.1587%;\"\u003eStorage\u003c\/td\u003e\n\u003ctd style=\"width: 82.4723%;\"\u003eGenerally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at \u0026lt; -20℃ for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 39.1875px;\" data-mce-style=\"height: 39.1875px;\"\u003e\n\u003ctd style=\"width: 17.1587%;\"\u003eShipping\u003c\/td\u003e\n\u003ctd style=\"width: 82.4723%;\"\u003eThis product is provided as lyophilized powder which is shipped with ice packs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 97.9688px;\" data-mce-style=\"height: 97.9688px;\"\u003e\n\u003ctd style=\"width: 17.1587%;\"\u003eFormulation\u003c\/td\u003e\n\u003ctd style=\"width: 82.4723%;\"\u003eLyophilized from sterile PBS, pH 7.4\u003cbr\u003eNormally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.\u003cbr\u003ePlease refer to the specific buffer information in the printed manual.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 50.7812px;\" data-mce-style=\"height: 50.7812px;\"\u003e\n\u003ctd style=\"width: 17.1587%;\"\u003eReconstitution\u003c\/td\u003e\n\u003ctd style=\"width: 82.4723%;\"\u003ePlease refer to the printed manual for detailed information.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"dt_tab3\" class=\"dt01\"\u003e\n\u003cdiv class=\"dt01\" id=\"dt_tab3\"\u003e\n\u003cdiv class=\"dt01\"\u003e\n\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"dt01\"\u003e\n\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"dt01\"\u003e\n\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"dt01\"\u003e\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003cspan\u003eBackground\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv class=\"dt01\"\u003e\n\u003cstrong\u003e\u003cspan class=\"title\"\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"dt01\"\u003eVEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as a major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Elabscience Biotechnology","offers":[{"title":"100μg","offer_id":40730939457594,"sku":"PKSH031931-100","price":1112.95,"currency_code":"USD","in_stock":true},{"title":"1mg","offer_id":40730939490362,"sku":"PKSH031931-1","price":6941.95,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0722\/7785\/files\/imy94K_4f208443-6add-4684-a6c6-6a7bd130af3f.jpg?v=1733201586","url":"https:\/\/www.msesupplies.com\/en-de\/products\/recombinant-human-vegfr2-flk-1-kdr-protein-fc-tag-active","provider":"MSE Supplies","version":"1.0","type":"link"}